首页> 外文期刊>Antiviral Research >Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
【24h】

Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.

机译:通过用表达嵌合血凝素的DNA结合小鼠中MHC I类限制性表位的疫苗接种,可增强针对H5N1流感病毒攻击的保护性免疫力。

获取原文
获取原文并翻译 | 示例
           

摘要

DNA vaccination is an effective means of eliciting both humoral and cellular immune responses. The hemagglutinin (HA) surface protein of influenza A virus is a major target of protective antibody responses induced by virus infection or by vaccination and is widely considered to be the antigen of choice for an influenza vaccine. Cytotoxic T lymphocyte (CTL) responses directed against the conserved nucleoprotein (NP) are thought to play an important role in clearing virus and promoting survival and recovery from influenza. In this study, we developed a novel DNA vaccine approach using a chimeric plasmid consisting of the HA of H5N1 influenza virus in which an MHC class I-restricted NP-specific CTL epitope (NP147-155) was inserted. Immunogenicity and antiviral efficacy of this vaccine was assessed in mouse models. A similar level of HA expression was achieved in 293T cells transfected with pHA/NP(147-155) compared to that with pHA. Besides eliciting the specific anti-HA antibody responses, vaccination using pHA/NP(147-155) in mice induced NP epitope-specific CD8(+) T cell responses, which are generally not inducible by vaccination with pHA alone. After H5N1 influenza virus challenge, BALB/c mice vaccinated with pHA/NP(147-155) exhibited reduced inflammation severity and lung viral titers compared to those vaccinated with pHA. Our work may contribute to improvement of HA-based influenza DNA vaccines.
机译:DNA疫苗接种是引发体液和细胞免疫应答的有效手段。甲型流感病毒的血凝素(HA)表面蛋白是由病毒感染或疫苗接种诱导的保护性抗体应答的主要目标,被广泛认为是流感疫苗的选择抗原。人们认为,针对保守核蛋白(NP)的细胞毒性T淋巴细胞(CTL)反应在清除病毒,促进流感的生存和恢复中起着重要作用。在这项研究中,我们使用由H5N1流感病毒的HA组成的嵌合质粒开发了一种新颖的DNA疫苗方法,其中插入了MHC I类限制性的NP特异性CTL表位(NP147-155)。在小鼠模型中评估了该疫苗的免疫原性和抗病毒效力。与pHA相比,在用pHA / NP(147-155)转染的293T细胞中达到了相似的HA表达水平。除了引起特异性抗HA抗体应答外,在小鼠中使用pHA / NP(147-155)进行疫苗接种还诱导了NP表位特异性CD8(+)T细胞应答,通常仅通过pHA疫苗接种是无法诱导的。在H5N1流感病毒攻击后,接种pHA / NP(147-155)的BALB / c小鼠与接种pHA的小鼠相比,炎症严重程度降低,肺病毒滴度降低。我们的工作可能有助于改进基于HA的流感DNA疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号